PubMed Health⌕ Search

PubMed · 8644217

How presumed is presumed consent?

Abstract

All things considered, one is tempted to answer the question in the title: How presumed is presumed consent? Not very, or not at all. It is evident that, regardless of the law, be it opting in or opting out, presumed consent or presumed nonconsent, the family is almost always consulted. The family has the preferential right of interpretation. Their interpretation of the attitude toward organ donation by the deceased is usually not contested, whether it is in agreement with or contrary to the stated (verbal or written) view of the deceased. This is understandable and proper; the sudden and unexpected death of a close relative is the start of the grieving process and, besides, relatives might take legal action if their opinion is not respected. Taken together, it can be argued that well-designed presumed consent legislation is the best system for many of the reasons stated. Foremost among these is that it offers a very good way to initiate consultations with the family. With due respect for any legal system, one does not discuss the legal aspects with the relatives. Since they are expected to honor the opinion of the deceased, there is reason for each of us to make our wishes regarding organ donation known to our relatives. It might relieve them of a difficult decision.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Gäbel. 1996. How presumed is presumed consent?. https://pubmed.ncbi.nlm.nih.gov/8644217/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A population-based study of cancer incidence in solid organ transplants from donors at various risk of neoplasia.

A population-based cohort study of recipients of organs from donors with a recognized history or active cancer has been conducted by linking the Italian National Registry of Transplanted Patients and the National Registry of Donors with Neoplasia Risk. Between 2002 and 2004, 8,198 solid organ transplants have been performed in Italy, 108 of them with organs from 59 cadaveric donors with various risk of neoplasia. There were two reported cases of nonmelanoma skin cancer during the follow up of the transplanted patients, which lasted 27.6+/-11.3 months (234 patient-years). In our study, recipients of organs from donors with various degree of neoplasia risk are exposed to a low risk of cancer transmission.

Cadaver↗

[Primary stability of the capsule-labrum complex after reconstruction with the Mitek Bioknotless anchor system in human cadaver models].

BACKGROUND: This study examines the postoperative stability of the Mitek Bioknotless anchor system with biomechanical draw-out pulling in human cadaver shoulders. METHOD: With simulation of anterior shoulder dislocation a test group (n=10, Ø 45 years) was tested against a native group (n=8, Ø 47 years). All shoulders were dissected up to the passive stabilizers. In the test group an artificial Bankart lesion was created and repaired with three Mitek Bioknotless anchors. The humeri of both groups were fixed in 60 degrees glenohumeral abduction and 90 degrees external rotation and then dislocated in a ventral direction. For evaluation purposes the ultimate draw-out strength, mode of failure, translation of humeral head, capsular slope, and bone density in the test group were measured. RESULTS: In the test group the ultimate strength was a median of 937 N (min. 554 N, max. 1,294 N) with 28 bony anchor dislocations, 1 suture rupture, and 1 capsular rupture, and in the native group with 6 Bankart and 2 HAGL lesions it was 1,214 N (708 N, 1,471 N). The bone density showed a positive correlation to the draw-out strength regarding cortical density and total density. CONCLUSION: Regarding the high draw-out strength the Mitek Bioknotless anchor system provides enough stability for early functional treatment.

Cadaver↗